Latvija - latviešu - Adama

adama - emulsija ūdenī - tau-fluvalināts - insekticīdi

Eiropas Savienība - latviešu - EMA (European Medicines Agency)

incyte biosciences distribution b.v. - ponatinibs - leukemia, myeloid; leukemia, lymphoid - antineoplastic agents, protein kinase inhibitors - iclusig is indicated in adult patients withchronic phase, accelerated phase, or blast phase chronic myeloid leukaemia (cml) who are resistant to dasatinib or nilotinib; who are intolerant to dasatinib or nilotinib and for whom subsequent treatment with imatinib is not clinically appropriate; or who have the t315i mutationphiladelphia chromosome positive acute lymphoblastic leukaemia (ph+ all) who are resistant to dasatinib; who are intolerant to dasatinib and for whom subsequent treatment with imatinib is not clinically appropriate; or who have the t315i mutation. skatīt nodaļas 4. 2 assessment of cardiovascular status prior to start of therapy and 4. 4 situations where an alternative treatment may be considered.

Eiropas Savienība - latviešu - EMA (European Medicines Agency)

alexion europe sas - ravulizumab - hemoglobīnūrija, paroksizmāla - selective immunosuppressants - paroxysmal nocturnal haemoglobinuria (pnh)ultomiris is indicated in the treatment of adult and paediatric patients with a body weight of 10 kg or above with pnh:- in patients with haemolysis with clinical symptom(s) indicative of high disease activity. - in patients who are clinically stable after having been treated with eculizumab for at least the past 6 months (see section 5. atypical haemolytic uremic syndrome (ahus)ultomiris is indicated in the treatment of patients with a body weight of 10 kg or above with ahus who are complement inhibitor treatment-naïve or have received eculizumab for at least 3 months and have evidence of response to eculizumab (see section 5. generalized myasthenia gravis (gmg)ultomiris is indicated as an add-on to standard therapy for the treatment of adult patients with gmg who are anti-acetylcholine receptor (achr) antibody-positive. neuromyelitis optica spectrum disorder (nmosd)ultomiris is indicated in the treatment of adult patients with nmosd who are anti-aquaporin 4 (aqp4) antibody-positive (see section 5. ultomiris is indicated in the treatment of adult patients with paroxysmal nocturnal haemoglobinuria (pnh):- in patients with haemolysis with clinical symptom(s) indicative of high disease activity. - in patients who are clinically stable after having been treated with eculizumab for at least the past 6 months. ultomiris is indicated in the treatment of adult patients with atypical haemolytic uremic syndrome (ahus) who are complement inhibitor treatment-naïve or have received eculizumab for at least 3 months and have evidence of response to eculizumab.

Latvija - latviešu - Pārtikas un veterinārais dienests, Zemkopības ministrija

aloe vera of europe b.v. - pulveris

Latvija - latviešu - Pārtikas un veterinārais dienests, Zemkopības ministrija

lfm pharma sa - pulveris

Latvija - latviešu - Pārtikas un veterinārais dienests, Zemkopības ministrija

bactolac pharmaceutical, inc. - pulveris

Latvija - latviešu - Pārtikas un veterinārais dienests, Zemkopības ministrija

vivatinell ltd. - sīrups

Latvija - latviešu - Pārtikas un veterinārais dienests, Zemkopības ministrija

sisel international ag - kapsula

Latvija - latviešu - Pārtikas un veterinārais dienests, Zemkopības ministrija

ozon, sia; pesočnaja 11, Žiguļovska, samaras apgabals - cits, apvalkota tablete

Latvija - latviešu - Pārtikas un veterinārais dienests, Zemkopības ministrija

laboratoria novapharm, - kapsula